CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
varenicline +1 moredrug
Likely dose
varenicline 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01000987
NCT01000987Phase 2Completed
CompareCT.gov

Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders

Yale University·interventional·Posted Oct 23, 2009·Updated Feb 19, 2018

In Brief

A Phase 2 clinical trial evaluating varenicline and placebo for Alcohol Reactivity. Completed, enrolled 44 participants across 1 site.

Detailed Summary

The purpose of this study is the examine the effect of varenicline on cognition to a high dose (0.08 g/dL) of alcohol (vs. placebo alcohol) over the ascending and descending limb of the blood alcohol curve.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Reactivity
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 23, 2009
Enrollment StartOct 1, 2009
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 16.7 years ago

Interventions

vareniclinedrug

1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.

placebodrug

placebo